 | • レポートコード：MRC2305C150 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、224ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社は、2021年に569.83百万ドルであった世界の糖化ヘモグロビン検査市場規模が、2022年には625.03百万ドルに成長し、その後年平均9.86％拡大して2027年には1,002.03百万ドルに達すると予測しています。本調査資料では、糖化ヘモグロビン検査の世界市場について総合的に調査・分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、種類別（実験室ベース検査、ポイントオブケア検査）分析、技術別（ボロン酸アフィニティークロマトグラフィー、直接酵素アッセイ、免疫測定法、イオン交換高速液体クロマトグラフィー（HPLC））分析、エンドユーザー別（学術＆研究機関、診断センター、病院）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの内容をまとめました。なお、本書内の企業情報には、A. Menarini Diagnostics Ltd.、Abbott Laboratories Inc.、Alere Inc.、ARKRAY, Inc.、Bayer AG、Beckman Coulter, Inc.、Bio-Rad Laboratories, Inc.、Ceragem Medisys、Chek Diagnostics、Daiichi Biotech、Danaher Corporation、DiaSys Diagnostic Systemsなどが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の糖化ヘモグロビン検査市場規模：種類別 - 実験室ベース検査の市場規模 - ポイントオブケア検査の市場規模 ・世界の糖化ヘモグロビン検査市場規模：技術別 - ボロン酸アフィニティークロマトグラフィーの市場規模 - 直接酵素アッセイの市場規模 - 免疫測定法の市場規模 - イオン交換高速液体クロマトグラフィー（HPLC）の市場規模 ・世界の糖化ヘモグロビン検査市場規模：エンドユーザー別 - 学術＆研究機関における市場規模 - 診断センターにおける市場規模 - 病院における市場規模 ・世界の糖化ヘモグロビン検査市場規模：地域別 - 南北アメリカの糖化ヘモグロビン検査市場規模 アメリカの糖化ヘモグロビン検査市場規模 カナダの糖化ヘモグロビン検査市場規模 ブラジルの糖化ヘモグロビン検査市場規模 ... - アジア太平洋の糖化ヘモグロビン検査市場規模 日本の糖化ヘモグロビン検査市場規模 中国の糖化ヘモグロビン検査市場規模 インドの糖化ヘモグロビン検査市場規模 韓国の糖化ヘモグロビン検査市場規模 台湾の糖化ヘモグロビン検査市場規模 ... - ヨーロッパ/中東/アフリカの糖化ヘモグロビン検査市場規模 イギリスの糖化ヘモグロビン検査市場規模 ドイツの糖化ヘモグロビン検査市場規模 フランスの糖化ヘモグロビン検査市場規模 ロシアの糖化ヘモグロビン検査市場規模 ... - その他地域の糖化ヘモグロビン検査市場規模 ・競争状況 ・企業情報 |
The Global Glycated Hemoglobin Testing Market size was estimated at USD 569.83 million in 2021 and expected to reach USD 625.03 million in 2022, and is projected to grow at a CAGR 9.86% to reach USD 1,002.03 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Glycated Hemoglobin Testing to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Type, the market was studied across Laboratory Based Tests and Point-of-care Test.
Based on Technique, the market was studied across Boronate Affinity Chromatography, Direct Enzymatic Assay, Immunoassay, and Ion-exchange High-Performance Liquid Chromatography (HPLC).
Based on End-User, the market was studied across Academic & Research Institutes, Diagnostic Centers, and Hospitals.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Glycated Hemoglobin Testing market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Glycated Hemoglobin Testing Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Glycated Hemoglobin Testing Market, including A. Menarini Diagnostics Ltd., Abbott Laboratories Inc., Alere Inc., ARKRAY, Inc., Bayer AG, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., Ceragem Medisys, Chek Diagnostics, Daiichi Biotech, Danaher Corporation, DiaSys Diagnostic Systems, DiaSys Diagnostic Systems GmbH, Diazyme Laboratories, EKF Diagnostics, Roche Holdings AG, SEBIA, Sebia SA, Siemens AG, TaiDoc Technology Corporation, Tosoh Corporation, Trinity Biotech Inc, and Trinity Biotech Plc..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Glycated Hemoglobin Testing Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Glycated Hemoglobin Testing Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Glycated Hemoglobin Testing Market?
4. What is the competitive strategic window for opportunities in the Global Glycated Hemoglobin Testing Market?
5. What are the technology trends and regulatory frameworks in the Global Glycated Hemoglobin Testing Market?
6. What is the market share of the leading vendors in the Global Glycated Hemoglobin Testing Market?
7. What modes and strategic moves are considered suitable for entering the Global Glycated Hemoglobin Testing Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing incidence of various chronic diseases such as diabetes globally
5.1.1.2. Rising geriatric population leads to higher vulnerability for diseases
5.1.1.3. Rapid adoption attributed to patient self-care solutions
5.1.2. Restraints
5.1.2.1. High cost pertinent to glycated hemoglobin testing equipment
5.1.3. Opportunities
5.1.3.1. Emerging demand for home healthcare market such as rapid diagnostic tests and PCOT
5.1.3.2. Ongoing R&D activities for early diagnosis and efficient disease management
5.1.4. Challenges
5.1.4.1. Limitation of HbA1c tests and availability of substitutes
5.2. Cumulative Impact of COVID-19
6. Glycated Hemoglobin Testing Market, by Type
6.1. Introduction
6.2. Laboratory Based Tests
6.3. Point-of-care Test
7. Glycated Hemoglobin Testing Market, by Technique
7.1. Introduction
7.2. Boronate Affinity Chromatography
7.3. Direct Enzymatic Assay
7.4. Immunoassay
7.5. Ion-exchange High-Performance Liquid Chromatography (HPLC)
8. Glycated Hemoglobin Testing Market, by End-User
8.1. Introduction
8.2. Academic & Research Institutes
8.3. Diagnostic Centers
8.4. Hospitals
9. Americas Glycated Hemoglobin Testing Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Glycated Hemoglobin Testing Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Glycated Hemoglobin Testing Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. A. Menarini Diagnostics Ltd.
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Abbott Laboratories Inc.
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Alere Inc.
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. ARKRAY, Inc.
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Bayer AG
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. Beckman Coulter, Inc.
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Bio-Rad Laboratories, Inc.
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Ceragem Medisys
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Chek Diagnostics
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. Daiichi Biotech
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. Danaher Corporation
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. DiaSys Diagnostic Systems
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. DiaSys Diagnostic Systems GmbH
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Diazyme Laboratories
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. EKF Diagnostics
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Roche Holdings AG
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. SEBIA
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Sebia SA
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Siemens AG
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. TaiDoc Technology Corporation
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. Tosoh Corporation
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services
13.22. Trinity Biotech Inc
13.22.1. Business Overview
13.22.2. Key Executives
13.22.3. Product & Services
13.23. Trinity Biotech Plc.
13.23.1. Business Overview
13.23.2. Key Executives
13.23.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing